Molecular and pharmacological aspects of antiestrogen resistance

Robert Clarke, Todd Skaar, Kerrie B. Bouker, Natalie Davis, Y. Richard Lee, James N. Welch, Fabio Leonessa

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Endocrine therapy is effective in approximately one-third of all breast cancers and up to 80% of tumors that express both estrogen and progesterone receptors. Despite the low toxicity, good overall response rates, and additional benefits associated with its partial agonist activity, most Tamoxifen-responsive breast cancers acquire resistance. The development of new antiestrogens, both steroidal and non-steroidal, provides the opportunity for the development of non-cross-resistant therapies and the identification of additional mechanisms of action and resistance. Drug-specific pharmacologic mechanisms may confer a resistance phenotype, reflecting the complexities of both tumor biology/pharmacology and the molecular endocrinology of steroid hormone action. However, since all antiestrogens will be effective only in cells that express estrogen receptors (ER), many mechanisms will likely be directly related to ER expression and signaling. For example, loss of ER expression/function is likely to confer a cross-resistance phenotype across all structural classes of antiestrogens. Altered expression of ERα and ERβ, and/or signaling from transcription complexes driven by these receptors, may produce drug-specific resistance phenotypes. We have begun to study the possible changes in gene expression that may occur as cells acquire resistance to steroidal and non-steroidal antiestrogens. Our preliminary studies implicate the altered expression of several estrogen-regulated genes. However, resistance to antiestrogens is likely to be a multigene phenomenon, involving a network of interrelated signaling pathways. The way in which this network is adapted by cells may vary among tumors, consistent with the existence of a highly plastic and adaptable genotype within breast cancer cells.

Original languageEnglish (US)
Pages (from-to)71-84
Number of pages14
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume76
Issue number1-5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Pharmacology
Tumors
Breast Neoplasms
Phenotype
Endocrinology
Steroid hormones
Neoplasms
Progesterone Receptors
Tamoxifen
Transcription
Drug Resistance
Gene expression
Pharmaceutical Preparations
Plastics
Toxicity
Molecular Biology
Estrogens
Genes

Keywords

  • Antiestrogen resistance
  • Molecular aspects
  • Pharmacological aspects

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Molecular and pharmacological aspects of antiestrogen resistance. / Clarke, Robert; Skaar, Todd; Bouker, Kerrie B.; Davis, Natalie; Lee, Y. Richard; Welch, James N.; Leonessa, Fabio.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 76, No. 1-5, 2001, p. 71-84.

Research output: Contribution to journalArticle

Clarke, Robert ; Skaar, Todd ; Bouker, Kerrie B. ; Davis, Natalie ; Lee, Y. Richard ; Welch, James N. ; Leonessa, Fabio. / Molecular and pharmacological aspects of antiestrogen resistance. In: Journal of Steroid Biochemistry and Molecular Biology. 2001 ; Vol. 76, No. 1-5. pp. 71-84.
@article{1936b46a1a9c4669aefb30a266981ad6,
title = "Molecular and pharmacological aspects of antiestrogen resistance",
abstract = "Endocrine therapy is effective in approximately one-third of all breast cancers and up to 80{\%} of tumors that express both estrogen and progesterone receptors. Despite the low toxicity, good overall response rates, and additional benefits associated with its partial agonist activity, most Tamoxifen-responsive breast cancers acquire resistance. The development of new antiestrogens, both steroidal and non-steroidal, provides the opportunity for the development of non-cross-resistant therapies and the identification of additional mechanisms of action and resistance. Drug-specific pharmacologic mechanisms may confer a resistance phenotype, reflecting the complexities of both tumor biology/pharmacology and the molecular endocrinology of steroid hormone action. However, since all antiestrogens will be effective only in cells that express estrogen receptors (ER), many mechanisms will likely be directly related to ER expression and signaling. For example, loss of ER expression/function is likely to confer a cross-resistance phenotype across all structural classes of antiestrogens. Altered expression of ERα and ERβ, and/or signaling from transcription complexes driven by these receptors, may produce drug-specific resistance phenotypes. We have begun to study the possible changes in gene expression that may occur as cells acquire resistance to steroidal and non-steroidal antiestrogens. Our preliminary studies implicate the altered expression of several estrogen-regulated genes. However, resistance to antiestrogens is likely to be a multigene phenomenon, involving a network of interrelated signaling pathways. The way in which this network is adapted by cells may vary among tumors, consistent with the existence of a highly plastic and adaptable genotype within breast cancer cells.",
keywords = "Antiestrogen resistance, Molecular aspects, Pharmacological aspects",
author = "Robert Clarke and Todd Skaar and Bouker, {Kerrie B.} and Natalie Davis and Lee, {Y. Richard} and Welch, {James N.} and Fabio Leonessa",
year = "2001",
doi = "10.1016/S0960-0760(00)00193-X",
language = "English (US)",
volume = "76",
pages = "71--84",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-5",

}

TY - JOUR

T1 - Molecular and pharmacological aspects of antiestrogen resistance

AU - Clarke, Robert

AU - Skaar, Todd

AU - Bouker, Kerrie B.

AU - Davis, Natalie

AU - Lee, Y. Richard

AU - Welch, James N.

AU - Leonessa, Fabio

PY - 2001

Y1 - 2001

N2 - Endocrine therapy is effective in approximately one-third of all breast cancers and up to 80% of tumors that express both estrogen and progesterone receptors. Despite the low toxicity, good overall response rates, and additional benefits associated with its partial agonist activity, most Tamoxifen-responsive breast cancers acquire resistance. The development of new antiestrogens, both steroidal and non-steroidal, provides the opportunity for the development of non-cross-resistant therapies and the identification of additional mechanisms of action and resistance. Drug-specific pharmacologic mechanisms may confer a resistance phenotype, reflecting the complexities of both tumor biology/pharmacology and the molecular endocrinology of steroid hormone action. However, since all antiestrogens will be effective only in cells that express estrogen receptors (ER), many mechanisms will likely be directly related to ER expression and signaling. For example, loss of ER expression/function is likely to confer a cross-resistance phenotype across all structural classes of antiestrogens. Altered expression of ERα and ERβ, and/or signaling from transcription complexes driven by these receptors, may produce drug-specific resistance phenotypes. We have begun to study the possible changes in gene expression that may occur as cells acquire resistance to steroidal and non-steroidal antiestrogens. Our preliminary studies implicate the altered expression of several estrogen-regulated genes. However, resistance to antiestrogens is likely to be a multigene phenomenon, involving a network of interrelated signaling pathways. The way in which this network is adapted by cells may vary among tumors, consistent with the existence of a highly plastic and adaptable genotype within breast cancer cells.

AB - Endocrine therapy is effective in approximately one-third of all breast cancers and up to 80% of tumors that express both estrogen and progesterone receptors. Despite the low toxicity, good overall response rates, and additional benefits associated with its partial agonist activity, most Tamoxifen-responsive breast cancers acquire resistance. The development of new antiestrogens, both steroidal and non-steroidal, provides the opportunity for the development of non-cross-resistant therapies and the identification of additional mechanisms of action and resistance. Drug-specific pharmacologic mechanisms may confer a resistance phenotype, reflecting the complexities of both tumor biology/pharmacology and the molecular endocrinology of steroid hormone action. However, since all antiestrogens will be effective only in cells that express estrogen receptors (ER), many mechanisms will likely be directly related to ER expression and signaling. For example, loss of ER expression/function is likely to confer a cross-resistance phenotype across all structural classes of antiestrogens. Altered expression of ERα and ERβ, and/or signaling from transcription complexes driven by these receptors, may produce drug-specific resistance phenotypes. We have begun to study the possible changes in gene expression that may occur as cells acquire resistance to steroidal and non-steroidal antiestrogens. Our preliminary studies implicate the altered expression of several estrogen-regulated genes. However, resistance to antiestrogens is likely to be a multigene phenomenon, involving a network of interrelated signaling pathways. The way in which this network is adapted by cells may vary among tumors, consistent with the existence of a highly plastic and adaptable genotype within breast cancer cells.

KW - Antiestrogen resistance

KW - Molecular aspects

KW - Pharmacological aspects

UR - http://www.scopus.com/inward/record.url?scp=0034992614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034992614&partnerID=8YFLogxK

U2 - 10.1016/S0960-0760(00)00193-X

DO - 10.1016/S0960-0760(00)00193-X

M3 - Article

C2 - 11384865

AN - SCOPUS:0034992614

VL - 76

SP - 71

EP - 84

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-5

ER -